ArticleFrontiers in medicine2026
Orelabrutinib in combination with pomalidomide for the successful treatment of primary vitreoretinal lymphoma: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary vitreoretinal lymphoma (PVRL) is a rare intraocular malignancy, often masquerading as chronic uveitis, which poses significant diagnostic and therapeutic challenges. Case presentation: A 55-year-old male with 1 year of progressive bilateral vision loss was initially misdiagnosed as having bilateral uveitis and received ineffective corticosteroid therapy at an outside medical center. Subsequent diagnostic vitrectomy of the right eye confirmed bilateral PVRL. He received intravitreal methotrexate (MTX) injections for treatment but developed MTX-induced toxic keratitis and progressive cataract, necessitating discontinuation of MTX. He was transitioned to systemic therapy with anti-CD20 monoclonal antibody (discontinued due to pulmonary infection) plus oral pomalidomide and orelabrutinib, which achieved complete clearance of vitreous disease, normalization of aqueous IL-10, and sustained clinical remission without significant hematologic or cardiac toxicities. Conclusion: Precise diagnosis and individualized treatment regimens are required for the therapy of PVRL. Besides, the orelabrutinib-pomalidomide combination represents a promising, well-tolerated targeted and chemo free therapy strategy for PVRL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.